| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
|
Lancet
|
2003
|
11.30
|
|
2
|
Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.
|
J Infect Dis
|
2005
|
3.59
|
|
3
|
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.
|
J Infect Dis
|
2005
|
2.54
|
|
4
|
Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations.
|
J Virol
|
2007
|
2.14
|
|
5
|
Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D.
|
J Acquir Immune Defic Syndr
|
2006
|
1.94
|
|
6
|
Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012).
|
J Acquir Immune Defic Syndr
|
2004
|
1.92
|
|
7
|
HIV-1 tropism and survival in vertically infected Ugandan infants.
|
J Infect Dis
|
2008
|
1.83
|
|
8
|
Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission.
|
J Infect Dis
|
2007
|
1.73
|
|
9
|
Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission.
|
J Infect Dis
|
2008
|
1.70
|
|
10
|
Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns.
|
AIDS
|
2005
|
1.58
|
|
11
|
Early weaning of HIV-exposed uninfected infants and risk of serious gastroenteritis: Findings from two perinatal HIV prevention trials in Kampala, Uganda.
|
J Acquir Immune Defic Syndr
|
2010
|
1.50
|
|
12
|
Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D.
|
J Mol Diagn
|
2006
|
1.25
|
|
13
|
Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012.
|
J Acquir Immune Defic Syndr
|
2005
|
1.24
|
|
14
|
Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda.
|
J Acquir Immune Defic Syndr
|
2009
|
1.08
|
|
15
|
Associations of chemokine receptor polymorphisms With HIV-1 mother-to-child transmission in sub-Saharan Africa: possible modulation of genetic effects by antiretrovirals.
|
J Acquir Immune Defic Syndr
|
2008
|
1.04
|
|
16
|
Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine.
|
AIDS
|
2007
|
1.02
|
|
17
|
In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
|
AIDS Res Hum Retroviruses
|
2009
|
0.98
|
|
18
|
Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival.
|
J Acquir Immune Defic Syndr
|
2013
|
0.97
|
|
19
|
Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012.
|
J Acquir Immune Defic Syndr
|
2005
|
0.95
|
|
20
|
HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D.
|
AIDS Res Hum Retroviruses
|
2007
|
0.93
|
|
21
|
Identification of Ugandan HIV type 1 variants with unique patterns of recombination in pol involving subtypes A and D.
|
AIDS Res Hum Retroviruses
|
2002
|
0.91
|
|
22
|
Analysis of nevirapine resistance mutations in cloned HIV type 1 variants from HIV-infected Ugandan infants using a single-step amplification-sequencing method (AmpliSeq).
|
AIDS Res Hum Retroviruses
|
2008
|
0.87
|
|
23
|
Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D.
|
J Acquir Immune Defic Syndr
|
2006
|
0.86
|
|
24
|
Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infants.
|
AIDS Res Hum Retroviruses
|
2009
|
0.81
|
|
25
|
Human papillomavirus prevalence and cytopathology correlation in young Ugandan women using a low-cost liquid-based Pap preparation.
|
Diagn Cytopathol
|
2010
|
0.80
|
|
26
|
The costs associated with adverse event procedures for an international HIV clinical trial determined by activity-based costing.
|
J Acquir Immune Defic Syndr
|
2007
|
0.79
|
|
27
|
Total lymphocyte count: not a surrogate marker for risk of death in HIV-infected Ugandan children.
|
J Acquir Immune Defic Syndr
|
2008
|
0.79
|
|
28
|
Analysis of HIV tropism in Ugandan infants.
|
Curr HIV Res
|
2010
|
0.78
|
|
29
|
Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012).
|
J Acquir Immune Defic Syndr
|
2002
|
0.78
|
|
30
|
Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine.
|
AIDS Res Hum Retroviruses
|
2005
|
0.78
|